医药增强LOF(161035)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-1,291,191.37 |
73,170,877.56 |
44,762,476.02 |
-83,296,210.63 |
| 利息合计 |
50,593.75 |
99,221.86 |
44,884.60 |
111,108.26 |
| 其中:存款利息收入 |
50,593.75 |
99,221.86 |
44,884.60 |
90,830.72 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-381,395.29 |
53,953,517.26 |
16,091,570.57 |
-89,813,560.11 |
| 其中:股票投资收益 |
-3,948,511.09 |
47,784,912.89 |
11,704,789.12 |
-97,741,306.82 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
4,449.78 |
-6,921.77 |
-9,327.52 |
349,639.52 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
3,562,666.02 |
6,175,526.14 |
4,396,108.97 |
7,578,107.19 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-1,116,342.62 |
18,778,912.16 |
28,440,247.45 |
6,241,959.12 |
| 其他收入 |
155,952.79 |
339,226.28 |
185,773.40 |
164,282.10 |
| 费用 |
3,186,208.61 |
6,541,292.48 |
3,339,864.27 |
7,504,166.81 |
| 管理人报酬 |
2,537,341.87 |
5,344,126.09 |
2,737,763.46 |
5,983,940.11 |
| 基金托管费 |
422,890.35 |
890,687.73 |
456,293.92 |
997,323.43 |
| 销售服务费 |
144,335.76 |
131,834.42 |
50,638.74 |
159,170.23 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
81,628.61 |
174,644.24 |
95,168.15 |
363,660.00 |
| 利润总额 |
-4,477,399.98 |
66,629,585.08 |
41,422,611.75 |
-90,800,377.44 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年